Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy

Wu, Shikai; Zhang, Yang; Xu, Li‐Yan; Dai, Yun; Teng, Yuee; Ma, Shanshan; Ho, Seong-Hyun; Kim, Jong-Mook; Yu, Seung Shin; Kim, Sun‐Young; Song, Santai

doi:10.1007/s00520-011-1290-x

Cited by 38 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the role of IL-11 in bone marrow failure syndromes, such as aplastic anemia and myelodysplastic syndrome, is being investigated in clinical trials [76,77]. On the other hand, to reduce the side effects and increase the activity of IL-11, a modified form of this cytokine, called IL-11 mutein was developed, which showed a promising profile with an increased potency and better safety in recent phase I and II clinical trials [78].…”

Section: Hematopoietic Activitiesmentioning

confidence: 99%

A panoramic review and in silico analysis of IL-11 structure and function

Negahdaripour

Nezafat

Ghasemi

2016

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Section: Hematopoietic Activitiesmentioning

confidence: 99%

A panoramic review and in silico analysis of IL-11 structure and function

Negahdaripour

Nezafat

Ghasemi

2016

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

“…[13][14][15] Up to date, the most effective approaches for treating the life-threatening complications of thrombocytopenia are platelet transfusion and supplementation with cytokines or thrombopoietic agents. [16][17][18][19] Nonetheless, their use is limited by side effects, costs and availability of blood donors. Therefore, more efficacious treatments to raise platelet count are needed.…”

Section: Introductionmentioning

confidence: 99%

2-Arachidonoylglycerol enhances platelet formation from human megakaryoblasts

et al. 2014

View full text Add to dashboard Cite

Platelets modulate vascular system integrity, and their loss is critical in haematological pathologies and after chemotherapy. Therefore, identification of molecules enhancing platelet production would be useful to counteract thrombocytopenia. We have previously shown that 2-arachidonoylglycerol (2-AG) acts as a true agonist of platelets, as well as it commits erythroid precursors toward the megakaryocytic lineage. Against this background, we sought to further interrogate the role of 2-AG in megakaryocyte/platelet physiology by investigating terminal differentiation, and subsequent thrombopoiesis. To this end, we used MEG-01 cells, a human megakaryoblastic cell line able to produce in vitro platelet-like particles.2-AG increased the number of cells showing ruffled surface and enhanced surface expression of specific megakaryocyte/platelet surface antigens, typical hallmarks of terminal megakaryocytic differentiation and platelet production. Changes in cytoskeleton modeling also occurred in differentiated megakaryocytes and blebbing platelets. 2-AG acted by binding to CB 1 and CB 2 receptors, because specific antagonists reverted its effect. Platelets were split off from megakaryocytes and were functional: they contained the platelet-specific surface markers CD61 and CD49, whose levels increased following stimulation with a natural agonist like collagen. Given the importance of 2-AG for driving megakaryopoiesis and thrombopoiesis, not surprisingly we found that its hydrolytic enzymes were tightly controlled by classical inducers of megakaryocyte differentiation.In conclusion 2-AG, by triggering megakaryocyte maturation and platelet release, may have clinical efficacy to counteract thrombocytopenia-related diseases.

show abstract

“…Additionally, chemotherapy-induced thrombocytopenia (CIT) is the most important cause of thrombocytopenia in patients with cancer [4]. Severe CIT not only has a risk of lifethreatening hemorrhagic complications but also may necessitate dose reduction and/or delay in chemotherapy schedules [3,[5][6][7][8]. Previous studies have indicated that various factors, such as platinum-based regimen, multiple high-risk chemotherapy treatments, multiple primary tumors, patients with lung cancer, and baseline thrombocyte count, have a high predictive value for CIT (3).…”

Section: Introductionmentioning

confidence: 99%

“…The demographic, clinical, laboratory, and pathological characteristics of Group 1 with CIT (n = 51, 40 %) and Group 2 without CIT (n = 80, 60 %) are displayed in Table 1. A total of 1,490 chemotherapy cycles were administered (median 10.6 cycles, range [6][7][8][9][10][11][12]. The median interval between cycles was 18 days (range 13-28).…”

Section: Introductionmentioning

confidence: 99%

Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?

Tanrıverdi

2014

Med Oncol

View full text Add to dashboard Cite

Chemotherapy-induced thrombocytopenia (CIT) is the most important cause of thrombocytopenia in cancer patients. In this paper, I discussed the effect of ABO blood group on CIT in patients with stage III colon cancer. In a pilot study, a total of 131 (72 men, 55 %) eligible patients with stage III colon cancer were divided into two groups according to whether they had CIT. Both groups were compared using demographic, histopathological, and laboratory variables. CIT was detected in 51 (40 %) of 131 patients. The incidence of CIT had a significant increased in patients with 0 blood group compared to other blood groups. It was concluded that the relationship between blood group 0 and the presence of CIT in patients with stage III colon cancer is independent of other study variables (P = 0.035, OR 3.14, 95 % CI 1.16-7.01). In conclusion, I hypothesized that 0 blood group may predict to differentiate high-risk patients for CIT.

show abstract

Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy

Abstract: This study shows that mIL-11 is well tolerated and has thrombopoietic activity equivalent to one third of the clinical dose of rhIL-11, indicating the potential of mIL-11 for use in the treatment of CIT.

Cited by 38 publications

References 21 publications

A panoramic review and in silico analysis of IL-11 structure and function

A panoramic review and in silico analysis of IL-11 structure and function

2-Arachidonoylglycerol enhances platelet formation from human megakaryoblasts

Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?

Contact Info

Product

Resources

About